Zoetis Inc. (LON:0M3Q)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 54.57B |
| Revenue (ttm) | 7.19B |
| Net Income (ttm) | 1.95B |
| Shares Out | n/a |
| EPS (ttm) | 4.31 |
| PE Ratio | 28.00 |
| Forward PE | 25.59 |
| Dividend | 1.45 (0.90%) |
| Ex-Dividend Date | Apr 21, 2025 |
| Volume | 1,219 |
| Average Volume | 9,271 |
| Open | 160.35 |
| Previous Close | 160.01 |
| Day's Range | 160.35 - 164.25 |
| 52-Week Range | 147.05 - 201.92 |
| Beta | 0.93 |
| RSI | 60.09 |
| Earnings Date | May 6, 2025 |
About Zoetis
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]
Financial Performance
In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.
Financial numbers in USD Financial StatementsNews
Trade Tracker: Brenda Vingiello sells Zoetis and buys Quanta Services
Brenda Vingiello, Chief Investment Officer at Sand Hill Global Advisors, joins 'Halftime Report' to detail her latest trades.
Trade Tracker: Brenda Vingiello sells Zoetis and buys Quanta Services
Brenda Vingiello, Chief Investment Officer at Sand Hill Global Advisors, joins 'Halftime Report' to detail her latest trades.
Zoetis' Q1: Market Overreaction Or Justified Drop?
Zoetis: Solid Q1 Results And A Weaker Dollar Provide Support (Upgrade)
Zoetis shifts from sell to hold as solid earnings, strong balance sheet, and tailwinds like a weaker dollar suggest fair value and potential 8%+ returns.
Zoetis domestically manufactures 75% of its U.S. sales, says CEO Kristin Peck
Kristin Peck, Zoetis CEO, joins 'Closing Bell Overtime' to talk quarterly results, the animal health sector, raising its guidance, and more.
Zoetis domestically manufactures 75% of its U.S. sales, says CEO Kristin Peck
Kristin Peck, Zoetis CEO, joins 'Closing Bell Overtime' to talk quarterly results, the animal health sector, raising its guidance, and more.
Zoetis Inc. (ZTS) Q1 2025 Earnings Call Transcript
Zoetis down despite Q1 beats, boosting 2025 guidance
Zoetis Beats Wall Street Estimates, Revises 2025 Guidance To Include Tariffs Impact
Animal health firm Zoetis Inc (NYSE: ZTS) on Tuesday reported a first-quarter 2025 adjusted EPS of $1.48, up from $1.38 a year ago, beating the consensus of $1.39 . Adjusted net income for the first ...
Zoetis raises forecast for 2025 revenue, profit on weaker US dollar
Animal healthcare company Zoetis on Tuesday raised its forecasts for annual adjusted profit and revenue above Wall Street expectations, after beating first-quarter estimates, benefiting from a weak U....
Zoetis Inc. 2025 Q1 - Results - Earnings Call Presentation
Zoetis Non-GAAP EPS of $1.48 beats by $0.08, revenue of $2.2B beats by $10M
Zoetis Announces First Quarter 2025 Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2025 and updated its full year 2025 guidance. The company...
Earnings Scheduled For May 6, 2025
Companies Reporting Before The Bell • CareCloud (NASDAQ: CCLD) is likely to report quarterly earnings at $0.05 per share on revenue of $25.92 million. • Knife River Holding (NYSE: KNF) is likely to ...
Zoetis Q1 2025 Earnings Preview
Zoetis: Unleashing Margin Expansion; Initiate Strong Buy
Zoetis accelerates growth through high-margin companion animal drugs and strategic focus, supporting above-consensus EPS. Read why ZTS stock is a strong buy.
P/E Ratio Insights for Zoetis
Looking into the current session, Zoetis Inc. (NYSE: ZTS) shares are trading at $158.35, after a 1.73% increase. Moreover, over the past month, the stock spiked by 3.76% , but in the past year, decre...
Elanco vs Zoetis stock: Sarat Sethi picks a side
Zoetis Inc (NYSE: ZTS) is a relatively better pick than Elanco Animal Health Inc (NYSE: ELAN) for those interested in gaining exposure to the pets category, says Sarat Sethi. He's a managing partner a...
Trade Tracker: Sarat Sethi buys Zoetis and sells Elanco
Sarat Sethi, Managing Partner at DCLA, joins CNBC's "Halftime Report" to detail his latest trades.
Trade Tracker: Sarat Sethi buys Zoetis and sells Elanco
Sarat Sethi, Managing Partner at DCLA, joins CNBC's "Halftime Report" to detail his latest trades.
Looking Into Zoetis's Recent Short Interest
Zoetis's (NYSE: ZTS) short percent of float has fallen 3.14% since its last report. The company recently reported that it has 6.90 million shares sold short , which is 1.54% of all regular shares tha...
My Top 15 High-Growth Dividend Stocks For April 2025
My Top 15 High-Growth Dividend stocks outperformed SPY and VIG in March, posting a loss of 3.26% compared to SPY's 5.86% and VIG's 4.50%. The April 2025 list offers an average dividend yield of 1.25% ...
Zoetis' Stock Is About as Cheap as It's Ever Been. 1 Thing to Know Before You Buy.
Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck...